Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 20Expanded_access 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2

Interventions

trametinib 3dabrafenib 3talimogene laherparepvec 2pembrolizumab 2Nivolumab 2Ipilimumab 2ulixertinib 1tebentafusp 1pegilodecakin 1omaveloxolone 1lifileucel 1efineptakin alfa 1balstilimab 1aldesleukin 1Melphalan 1Cyclophosphamide 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Melanoma × talimogene laherparepvec × Clear all
NCT02297529 2019-10-31

Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma

Amgen

No longer available
Dermatologic

Melanoma

NCT02147951 2016-03-01

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Amgen

No longer available
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡